Segment, Geographic and Other Revenue Information - Revenues by Products - Footnotes (Details) treatmentCourse in Millions, $ in Millions		2 Months Ended	3 Months Ended			9 Months Ended
		Feb. 29, 2024 treatmentCourse	Sep. 29, 2024 USD ($)	Mar. 31, 2024 USD ($)	Oct. 01, 2023 USD ($)	Sep. 29, 2024 USD ($)	Oct. 01, 2023 USD ($)	Dec. 31, 2023 USD ($) treatmentCourse
Revenue from External Customer [Line Items]
Net sales			$ 17,702		$ 13,491	$ 45,864	$ 44,984
Biopharma [Member]
Revenue from External Customer [Line Items]
Net sales			17,392		13,188	44,987	44,051
Specialty Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Net sales			4,289		3,763	12,215	11,035
Paxlovid [Member]
Revenue from External Customer [Line Items]
Favorable adjustment for government emergency use authorization inventory returned to the company during the period				$ 771		771
Reversal of revenue								$ 3,500
Government emergency use authorization inventory returned to the company during the period, number of treatment courses | treatmentCourse		5.1
Estimated government emergency use authorization inventory to be returned to company, number of treatment courses | treatmentCourse								6.5
Paxlovid [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Favorable adjustment for government emergency use authorization inventory returned to the company during the period				$ 771		771
Octagam [Member] | Specialty Care [Member] | Biopharma [Member]
Revenue from External Customer [Line Items]
Net sales	[1]		221		$ 53	400	$ 164
Octagam [Member] | Specialty Care [Member] | Biopharma [Member] | Commercialization Partner
Revenue from External Customer [Line Items]
Net sales			129			129
Paxlovid, NDA-Labeled, U.S. Strategic National Stockpile [Member]
Revenue from External Customer [Line Items]
Revenues			$ 442			$ 442

[1] The third quarter and first nine months of 2024 include $129 million related to a one-time sales true-up settlement agreement with our commercialization partner.